Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rani Therapeutics Holdings (RANI) Non-cash Items (2021 - 2025)

Rani Therapeutics Holdings (RANI) has 5 years of Non-cash Items data on record, last reported at $8.4 million in Q3 2025.

  • For Q3 2025, Non-cash Items rose 78.21% year-over-year to $8.4 million; the TTM value through Sep 2025 reached $8.4 million, up 78.21%, while the annual FY2023 figure was $13.4 million, N/A changed from the prior year.
  • Non-cash Items reached $8.4 million in Q3 2025 per RANI's latest filing, up from $5.7 million in the prior quarter.
  • Across five years, Non-cash Items topped out at $14.5 million in Q2 2021 and bottomed at $100000.0 in Q2 2022.
  • Average Non-cash Items over 5 years is $6.0 million, with a median of $5.2 million recorded in 2024.
  • Peak YoY movement for Non-cash Items: tumbled 99.31% in 2022, then skyrocketed 78.21% in 2025.
  • A 5-year view of Non-cash Items shows it stood at $976000.0 in 2021, then decreased by 12.71% to $851908.0 in 2022, then soared by 1470.24% to $13.4 million in 2023, then crashed by 64.76% to $4.7 million in 2024, then surged by 78.21% to $8.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Non-cash Items were $8.4 million in Q3 2025, $5.7 million in Q1 2025, and $4.7 million in Q3 2024.